New and Approved: Review of Radiopharmaceutical Therapies


Newly-approved radiopharmaceuticals often hit the market with little to no information on production, or in-depth guidance on clinical use. Come to this session to hear two experts in the field provides a practical overview of the new FDA-approved radiopharmaceuticals Lutathera and Azedra, and their use in oncology and nuclear medicine.

Pharmacist Learning Objectives

At the completion of this knowledge-based activity, participants will be able to:

  1. Review the process for preparing, dispensing, and administering Lutathera and imaging before and after therapy. This includes describing the radiolabeling process of Lutetium-177 dotatate, quality control methods, FDA-approved use of Lutathera, and factors to consider when treating patients, including patient room preparation.
  2. Review the clinical trials findings, FDA-approved use, treatment guidelines, mechanism of action, administration, imaging and other factors to consider when treating patients with Azedra, including patient room requirements

Joint Providership

This activity is approved for Board Certified Nuclear Pharmacist (BCNP) recertification credits.

Elmer Santos, MD
Assistant Professor
The University of Texas MD Anderson Cancer Center
Krisztian Sandidge,
Advanced Accelerator Applications
Learning Level: Level 2
Track: Nuclear Pharmacy
Session Time Slot(s): 
Sunday, March 24
4:15 PM - 6:15 PM
Washington State Convention Center - Room 615-617
ACPE Pharmacist: 0202-0000-19-072-L01-P
CEUs Pharmacist: .2
Activity Type: